Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 228

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial

Lee, Jeeyun, Kim, Seung Tae, Kim, Kyung, Lee, Hyuk, Kozarewa, Iwanka, Mortimer, Peter G.S., Odegaard, Justin I., Harrington, Elizabeth A., Lee, Juyoung, Lee, Taehyang, Oh, Sung Yong, Kang, Jung-Hun, Kim, Jung Hoon, Kim, Youjin, Ji, Jun Ho, Kim, Young Saing, Lee, Kyoung Eun, Kim, Jinchul, Sohn, Tae Sung, An, Ji Yeong, Choi, Min-Gew, Lee, Jun Ho, Bae, Jae Moon, Kim, Sung, Kim, Jae J., Min, Yang Won, Min, Byung-Hoon, Kim, Nayoung K.D., Luke, Sally, Kim, Young Hwa, Hong, Jung Yong, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Talasaz, AmirAli, Hollingsworth, Simon J., Kim, Kyoung-Mee, Kang, Won Ki·2019·Cancer Discovery

Abstract

The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was designed to classify patients with metastatic gastric cancer based on clinical sequencing and focused on eight different biomarker groups (RAS aberration, TP53 mutation, PIK3CA mutation/amplification, MET amplification, MET overexpression, all negative, TSC2 deficient, or RICTOR amplification) to assign patients to one of the 10 associated clinical trials in second-line (2L) treatment. Capivasertib (AKT inhibitor), savolitinib (MET inhibitor), selumetinib (MEK inhibitor), adavosertib (WEE1 inhibitor), and vistusertib (TORC inhibitor) were tested with or without chemotherapy. Seven hundred seventy-two patients with gastric cancer were enrolled, and sequencing was successfully achieved in 715 patients (92.6%). When molecular screening was linked to seamless immediate access to parallel matched trials, 14.7% of patients received biomarker-assigned drug treatment. The biomarker-assigned treatment cohort had encouraging response rates and survival when compared with conventional 2L chemotherapy. Circulating tumor (ctDNA) analysis demonstrated good correlation between high MET copy number by ctDNA and response to savolitinib. Significance: Prospective clinical sequencing revealed that baseline heterogeneity between tumor samples from different patients affected response to biomarker-selected therapies. VIKTORY is the first and largest platform study in gastric cancer and supports both the feasibility of tumor profiling and its clinical utility. This article is highlighted in the In This Issue feature, p. 1325

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-0442

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 228

Metadata

Authors
Lee, J., Kim, S. T., Kim, K., Lee, H., Kozarewa, I., Mortimer, P. G. S., Odegaard, J. I., Harrington, E. A., Lee, J., Lee, T., Oh, S. Y., Kang, J.-H., Kim, J. H., Kim, Y., Ji, J. H., Kim, Y. S., Lee, K. E., Kim, J., Sohn, T. S., An, J. Y., Choi, M.-G., Lee, J. H., Bae, J. M., Kim, S., Kim, J. J., Min, Y. W., Min, B.-H., Kim, N. K. D., Luke, S., Kim, Y. H., Hong, J. Y., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Talasaz, A., Hollingsworth, S. J., Kim, K.-M., & Kang, W. K.
Venue
Cancer Discovery
Published
2019-10-01
Volume
9
Issue
10
Pages
1388-1405
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2958034733
Cited by
228
References
6
FWCI
21.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. https://app.cochat.ai/papers/10.1158/2159-8290.cd-19-0442
The paper
Lee, J., Kim, S. T., Kim, K., Lee, H., Kozarewa, I., Mortimer, P. G. S., Odegaard, J. I., Harrington, E. A., Lee, J., Lee, T., Oh, S. Y., Kang, J.-H., Kim, J. H., Kim, Y., Ji, J. H., Kim, Y. S., Lee, K. E., Kim, J., Sohn, T. S., . . . Kang, W. K. (2019). Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-19-0442

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.